Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART-Reference-Cited by-同舟云学术

Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART

Published:2018-10-31 Issue:2 Volume:74 Page:473-479
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Derache Anne¹²,Iwuji Collins C¹³⁴,Danaviah Siva¹,Giandhari Jennifer⁵,Marcelin Anne-Geneviève⁶,Calvez Vincent⁶,de Oliveira Tulio⁵,Dabis François⁷,Pillay Deenan¹²,Gupta Ravindra K¹²

Affiliation:

1. Africa Health Research Institute (AHRI), KwaZulu-Natal, South Africa

2. Division of Infection and Immunity, University College London, London, UK

3. Institute for Global Health, University College London, London, UK

4. Department of Global Health and Infection, Brighton and Sussex Medical School, Brighton, UK

5. KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa

6. Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, F-75013 Paris, France

7. Université de Bordeaux, ISPED, Centre INSERM 1219, Bordeaux, France

Funder

French National Agency for AIDS and Viral Hepatitis Research

ANRS

Deutsche Gesellschaft für Internationale Zusammenarbeit

GIZ

International Initiative for Impact Evaluation, Inc

Bill & Melinda Gates Foundation

Wellcome Trust

Publisher

Oxford University Press (OUP)

Subject